|
Market Cap (17-May) $36,803,800 (436th) |
Close (30-Jun) $0.310 |
Volume (30-Jun) 965,700 |
Shortsold (5-May) 630,735 (0.15%) (400th) |
|
52w High $0.130 |
52w Low $0.086 |
P/E 312.50 |
EPS -0.03 |
SPL released this announcement to the ASX on 1 March 2022, 11:27. The announcement is marked as price sensitive, and is 5 page(s) in length and 333.51kb in size.
You can view all announcements from SPL and see how they appear on a price chart on the announcements page.
At the date of this announcement, SPL was 3.001% short sold according to ASIC data. It was ranked the 59th most shorted stock on the ASX. It remains ranked 400th as of the latest reported data (05 May 2025).
| Other Recent Announcements from SPL | |
|---|---|
| Clinical Trial Update | 27 June 2023, 9:57 |
| Life Sciences Investor Forum Presentation | 23 June 2023, 10:42 |
| Starpharma to present at Life Sciences Investor Forum | 22 June 2023, 12:48 |
| SPL7013 in VIRALEZE virucidal against Omicron | 1 March 2022, 11:27 |
| Dr Jeff Davies appointed as non-executive director | 24 February 2022, 9:08 |
| Interim Report and Half-Year Financial Results | 21 February 2022, 9:32 |
| VIRALEZE distribution in Saudi Arabia - supplementary info | 4 February 2022, 16:04 |
You must be logged in to post a reply.
Starpharma Holdings 